ClinicalTrials.gg
Active, not recruitingNCT04511364Updated Jan 31, 2025

CONFIRM EXTENSION - Long-term Follow-up Study of Patients Treated with AGN1 LOEP

An interventional study of Clinical imaging is performed during the 24 and 60 month follow-up visits in Osteoporosis, sponsored by AgNovos Healthcare, LLC. Active, not recruiting at 1 site in Belgium. Open to female participants. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by AgNovos Healthcare, LLC · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Osteoporosis with a site in Belgium — 4 open to participants now, 5 under way, none of them phase 3. Osteoporosis · Belgium.

Planned enrollment
21st of 27
60 · median 218
Started
2020
with 1 other
No phase
9 of 32
2 open now
Registered
27th of 32
by date
Lead sponsor
6 of 32
AgNovos Healthcare, LLC

Among the 32 studies in Osteoporosis with a site in Belgium, this one is the 21st largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2020, is one of 9 with no phase, and was the 27th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

4 of the 32 studies in Osteoporosis with a site in Belgium are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Osteoporosis with a site in Belgium, or all of them as a file.
02

Study summary

The study is designed as a multi-center study within Europe in up to 60 patients treated with the AGN1 LOEP Kit in CONFIRM. This will be a non-randomized and non-blinded study. The study will collect long-term follow-up data on the safety and clinical performance of AGN1 LOEP.

To qualify, subjects must have previously consented, enrolled, and been treated with the AGN1 LOEP kit in CONFIRM (AgNovos Study PST-EU-101.1).

Follow-up evaluations will be conducted at 24, 36, 48 and 60 months from the date the subject originally received the AGN1 LOEP treatment. Subjects will receive DXA and X-ray imaging at the 24- and 60-month follow-up visits. The 36- and 48-month follow-up evaluations will be conducted by phone. All timepoints will include general health and medical record review.

03

Conditions studied

  • Osteoporosis

Keywords

  • local osteo-enhancement procedure
  • hip fracture/prevention and control
  • calcium phosphate
  • calcium sulphate
  • LOEP
  • CONFIRM Extension
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject had previously enrolled in CONFIRM and received AGN1 LOEP treatment.
  • Subject has willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study.
  • Subject is capable of giving written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Subject was withdrawn from CONFIRM.
  • Subject has severe comorbidity or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    AGN1 treated patients

    Patients have been treated with the AGN1 LOEP kit in AgNovos study PST-EU-101.1. An X-ray and DXA scan are performed at 24 and 60 months post AGN1 LOEP treatment.

    Other: Clinical imaging is performed during the 24 and 60 month follow-up visits

Interventions

  • OtherClinical imaging is performed during the 24 and 60 month follow-up visits

    X-ray and DXA scan

06

What researchers measure

Primary outcomes

  1. Change in DXA score at 24 months

    Change in DXA score of treated hip from baseline pre-AGN1 LOEP to 24 months post-treatment.

    Time frame: 24 months

Secondary outcomes

  1. Change in DXA score at 60 months

    Change in DXA score of treated hip from pre-AGN1 LOEP to 60 months post-treatment.

    Time frame: 60 months

  2. Hip fracture incidence

    The incidence of hip fracture on the treated side during the follow-up period through 60 months post-AGN1 LOEP treatment.

    Time frame: 60 months

  3. Radiologic bone formation

    Radiologic appearance of bone formation as assessed by X-ray at 24 and 60 months post-treatment.

    Time frame: 60 months

Other outcomes

  1. Safety evaluation

    The incidence of all serious adverse events during follow-up determined to be at least possibly related to the procedure and/or device through 60 months post-AGN1 LOEP treatment.

    Time frame: 60 months

07

Study locations

1 site
08

References and documents

Publications

  • Pajor A, Grof J, Idei M, Menyhart J, Zsolnai B. Utero-inhibin: a new substance inhibiting uterine contraction, isolated from amniotic fluid. Acta Physiol Acad Sci Hung. 1982;59(4):325-8. PubMed 7170985 ↗
  • Harsoulis P, Ekonomou A, Leontsini M, Efthimiou E, Gerasimidis T, Vlotidis J, Sbarounis C. Fine needle aspiration biopsy cytology in the diagnosis of thyroid cancer. Acta Endocrinol Suppl (Copenh). 1984;265:50-1. doi: 10.1530/acta.0.107s0050. No abstract available. PubMed 6593990 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Dec 2025, 64 months after the start.

Of 239 interventional studies with no phase under Osteoporosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 50. This study's planned 64 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2020
First posted
Aug 13, 2020
StartActual
Aug 28, 2020
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04511364
Lead sponsor
AgNovos Healthcare, LLC
Responsible party
Sponsor
First posted
Aug 13, 2020
Start date
Aug 28, 2020
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 31, 2025

Study contacts

Jo De Schepper, MD
principal investigator · AZ Nikolaas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion